GT Biopharma showcased new preclinical data in an oral presentation at SITC demonstrating an enhanced effect of combining GTB-5550, a B7-H3-targeted tri-specific NK cell engager (TriKE®), with a KRAS inhibitor (KRASi),
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Cancer treatment is moving into a new phase, and immuno-oncology is right at the center of it. Instead of relying only on drugs that attack tumors directly, researchers are
SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant
SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on
Phase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026
Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins,
Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move
Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for
Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry
Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs
Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc.
Issued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /CNW/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody
